Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • KevonLooney@lemm.ee
    link
    fedilink
    arrow-up
    18
    arrow-down
    2
    ·
    1 year ago

    There are many types of “medical professionals”. Only a vast minority actually read and interpret trial data.

    I’m going to trust my direct experience with the drug (I know it works) and real world studies like below.

    Conclusions: This study suggests that in the era of Omicron and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.

    https://pubmed.ncbi.nlm.nih.gov/35653428/

    • SoleInvictus@lemmy.world
      link
      fedilink
      arrow-up
      10
      arrow-down
      4
      ·
      1 year ago

      Excuse me, that study only examined 140,219 patients. You’ll need WAY more, at least one million, to argue against the anecdotal opinion of a random, unspecified ‘medical professional’.

      /s so hard

      • thepianistfroggollum@lemmynsfw.com
        link
        fedilink
        English
        arrow-up
        2
        arrow-down
        5
        ·
        1 year ago

        Only 2.6% of the sample were given paxlovid, and they didn’t control for vaccination status.

        Also, it only covered 1 month nearly 2 years ago in a single country, and the virus has mutated several times since then.

        • SoleInvictus@lemmy.world
          link
          fedilink
          arrow-up
          2
          ·
          1 year ago

          The best part about having a background in statistics is watching people who don’t understand statistics try to explain why the math that doesn’t support their point actually does, somehow.

        • Muddybulldog@mylemmy.win
          link
          fedilink
          English
          arrow-up
          2
          ·
          1 year ago

          Paxlovid is a 3CL protease inhibitor. It modifies the primary enzyme that is common across all cornavirus.

    • FontMasterFlex@lemmy.world
      link
      fedilink
      arrow-up
      3
      arrow-down
      3
      ·
      1 year ago

      dude’s not saying it doesn’t work. he’s saying it doesn’t work as well as advertised. that perhaps doesn’t mean it’s only 50% effective for 100% people. perhaps it’s 100% effective for 20% of people. Think dude.

      • Jax
        link
        fedilink
        arrow-up
        3
        arrow-down
        1
        ·
        edit-2
        1 year ago

        Yeah I’m gonna go ahead and say the guy throwing out accusations like false advertising is the one that needs to think a little more.

        Paxlovid has only ever been advertised as something that “can reduce the risk of hospitalization and death by around 89%”.

        The idea that, somehow, all of the people associated with coming to the “89%” number are somehow magically also associated with a subset of the population that responds well to it is fucking nonsense. It’s the exact same garbage logic that conspiracy theorists use.

    • thepianistfroggollum@lemmynsfw.com
      link
      fedilink
      English
      arrow-up
      2
      arrow-down
      3
      ·
      1 year ago

      Ah, that was the era of omicron. We’re over 21 months and several variants past that now, and I was given the information about paxlovid last week.

      Also, that study only covers a single month in Israel in 2022 and only 2.6% of the sample was given paxlovid.